127.00
price down icon0.02%   -0.02
after-market After Hours: 126.99 -0.01 -0.01%
loading
Intra Cellular Therapies Inc stock is traded at $127.00, with a volume of 2.29M. It is down -0.02% in the last 24 hours and up +52.13% over the past month. Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$127.02
Open:
$126.91
24h Volume:
2.29M
Relative Volume:
1.11
Market Cap:
$13.49B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
-145.98
EPS:
-0.87
Net Cash Flow:
$-62.91M
1W Performance:
-0.06%
1M Performance:
+52.13%
6M Performance:
+62.61%
1Y Performance:
+85.70%
1-Day Range:
Value
$126.91
$127.24
1-Week Range:
Value
$126.91
$127.61
52-Week Range:
Value
$62.78
$128.00

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name
Name
Intra Cellular Therapies Inc
Name
Phone
(646) 440-9333
Name
Address
135 ROUTE 202/206, BEDMINSTER, NY
Name
Employee
561
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
ITCI's Discussions on Twitter

Compare ITCI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
127.00 13.49B 612.78M -86.37M -62.91M -0.87
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
172.71 77.92B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.70 43.43B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.57 43.27B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.84 20.21B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
153.29 15.52B 2.24B 385.90M 440.10M 3.73

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-06-24 Upgrade Piper Sandler Neutral → Overweight
Jan-03-24 Initiated Robert W. Baird Outperform
Dec-11-23 Initiated TD Cowen Outperform
Apr-20-23 Initiated Morgan Stanley Overweight
Aug-22-22 Downgrade Goldman Buy → Neutral
Jul-07-22 Initiated Mizuho Buy
Jun-14-22 Initiated UBS Buy
Apr-22-22 Initiated Piper Sandler Neutral
Feb-16-22 Initiated Goldman Buy
Sep-23-21 Initiated Needham Buy
Dec-15-20 Initiated BofA Securities Buy
Dec-10-20 Initiated Goldman Buy
Feb-20-20 Initiated Evercore ISI Outperform
Jan-31-20 Downgrade JP Morgan Overweight → Neutral
Dec-24-19 Reiterated Canaccord Genuity Buy
Aug-12-19 Initiated Jefferies Buy
Feb-26-18 Initiated JP Morgan Overweight
Feb-08-18 Initiated RBC Capital Mkts Outperform
Dec-15-17 Initiated Canaccord Genuity Buy
Nov-08-17 Upgrade SunTrust Hold → Buy
Sep-07-17 Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17 Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17 Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17 Downgrade Ladenburg Thalmann Buy → Neutral
May-02-17 Downgrade Leerink Partners Outperform → Mkt Perform
May-01-17 Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16 Initiated Cantor Fitzgerald Overweight
Sep-29-16 Reiterated RBC Capital Mkts Outperform
Sep-29-16 Downgrade SunTrust Buy → Neutral
View All

Intra Cellular Therapies Inc Stock (ITCI) Latest News

pulisher
01:00 AM

Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain - GlobeNewswire Inc.

01:00 AM
pulisher
Jan 29, 2025

R Squared Ltd Takes Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 29, 2025
pulisher
Jan 29, 2025

Moody Aldrich Partners LLC Sells 27,173 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 29, 2025
pulisher
Jan 29, 2025

SG Americas Securities LLC Purchases 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 29, 2025
pulisher
Jan 27, 2025

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 27, 2025
pulisher
Jan 26, 2025

(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 26, 2025
pulisher
Jan 24, 2025

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN

Jan 24, 2025
pulisher
Jan 23, 2025

StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Estimates ITCI FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga

Jan 22, 2025
pulisher
Jan 22, 2025

J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy - BioSpace

Jan 22, 2025
pulisher
Jan 22, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Given "Sector Perform" Rating at Royal Bank of Canada - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

J&J’s Intra-Cellular deal could signal more mega-mergers for 2025 - Chemistry World

Jan 22, 2025
pulisher
Jan 22, 2025

Barlow Wealth Partners Inc. Purchases Shares of 2,200 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Johnson & Johnson acquires Intra-Cellular Therapies - Pf Media

Jan 22, 2025
pulisher
Jan 22, 2025

Research Analysts Issue Forecasts for ITCI FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

RBC Capital cuts Intra-Cellular stock rating, hikes target to $132 - MSN

Jan 22, 2025
pulisher
Jan 21, 2025

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSEENFN), Intra-Cellular Therapies, Inc. (NasdaqITCI), H&E Equipment Services, Inc. (NasdaqHEES), Shutterstock, Inc. (NYSE - GlobeNewswire Inc.

Jan 21, 2025
pulisher
Jan 20, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar

Jan 20, 2025
pulisher
Jan 20, 2025

Intra-Cellular Therapies Enters Merger Agreement with Johnson & Johnson - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Johnson & Johnson to acquire Intra-Cellular Therapies - Scientist Live

Jan 20, 2025
pulisher
Jan 20, 2025

Avanza Fonder AB Buys New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - MSN

Jan 20, 2025
pulisher
Jan 19, 2025

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

J&J to buy Intra-Cellular Therapies for $14.6 billion - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’ - Insider Monkey

Jan 18, 2025
pulisher
Jan 18, 2025

Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires - Insider Monkey

Jan 18, 2025
pulisher
Jan 17, 2025

J&J to Acquire Intra-Cellular for About $14.6 Billion - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Johnson & Johnson pays $14.6 billion for mental health biopharma company - DOTmed HealthCare Business News

Jan 17, 2025
pulisher
Jan 17, 2025

Is Johnson & Johnson Stock Set to Reward Long-Term Holders? - Benzinga

Jan 17, 2025
pulisher
Jan 17, 2025

Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says GlobalData - Express Pharma

Jan 17, 2025
pulisher
Jan 17, 2025

Johnson & Johnson exploring takeover of Intra-CellularBloomberg - MSN

Jan 17, 2025
pulisher
Jan 16, 2025

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Why Intra-Cellular (ITCI) Led the Monday Upsurge? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

J&J to acquire psychiatric drugs maker Intra-Cellular for $14.6 billion - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World

Jan 16, 2025

Intra Cellular Therapies Inc Stock (ITCI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$11.42
price up icon 0.79%
$153.29
price up icon 1.73%
$17.84
price down icon 3.78%
$92.79
price up icon 0.28%
$12.47
price up icon 1.46%
Cap:     |  Volume (24h):